InsidersTradesSigma
Track the Achieve Life Sciences, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Achieve Life Sciences, INC. has logged 47 insider filings. Market capitalisation: €825.3m. The latest transaction was disclosed on 21 August 2026 (Cession). Among the most active insiders: Bencich John. All data is accessible without an account.
47
Insider Decl.
n/a
Thresholds
€197,470
7 ops.
Buy Volume
€151,265
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Achieve Life Sciences, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$13.83.
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations47 total
20,626 shares@ US$8.493Common StockSEC:0001193125-26-361182:0
20,626 shares@ US$7.520.021% mcap54.6% of flowCommonSEC144:0001949846-26-000528
168,000 shares0Common StockSEC:0001193125-25-211404:0
297,500 shares0Common StockSEC:0001193125-25-211392:0
455,000 shares0Common StockSEC:0000950170-25-113591:0
110,000 shares0Common StockSEC:0000950170-25-113588:0
69,000 shares0Common StockSEC:0000950170-25-113581:0
10,000 shares@ US$2.859823.6% of flowCommon StockSEC:0000950170-25-042060:0
Canonical exit: 15 Jun 2025 (T+90)
10,000 shares@ US$2.8887100.0% of flowCommon StockSEC:0000950170-25-042074:0
Canonical exit: 15 Jun 2025 (T+90)
2,660 shares@ US$3.6715.6% of flowCommon StockSEC:0000950170-24-099082:0
5,000 shares@ US$3.677.3% of flowCommon StockSEC:0000950170-24-099074:0
6,088 shares@ US$4.5111.3% of flowCommon StockSEC:0000950170-24-046936:1
10,125 shares@ US$4.5138.5% of flowCommon StockSEC:0000950170-24-046962:1
3,957 shares@ US$4.5129.4% of flowCommon StockSEC:0000950170-24-046974:1
16,250 shares0Common StockSEC:0000950170-24-046974:0
25,000 shares0Common StockSEC:0000950170-24-046936:0
22,500 shares0Common StockSEC:0000950170-24-046962:0
10,000 shares@ US$4.58518.5% of flowCommon StockSEC:0000950170-24-027243:0
Canonical exit: 2 Jun 2024 (T+90)
10,000 shares@ US$4.58537.9% of flowCommon StockSEC:0000950170-24-027261:0
Canonical exit: 2 Jun 2024 (T+90)
5,000 shares@ US$5.5011.2% of flowCommon StockSEC:0001209191-23-033392:0
Canonical exit: 28 Aug 2023 (T+90)
25 of 47 declarations
关于 Achieve Life Sciences, INC.
Achieve Life Sciences, Inc.（股票代码：ACHV）是一家在美国纳斯达克市场上市的美国生物制药公司。该公司在华盛顿州博塞尔/西雅图和不列颠哥伦比亚省温哥华设有双重业务，但其企业身份和资本市场准入牢固地扎根于美国。Achieve 是一家专注于单一治疗主题：尼古丁依赖的专业制药公司。其主要资产是 cytisinicline，一种用于戒烟，并可能用于戒除电子烟的试验性疗法。([sec.gov](https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-20260415.htm?utm_source=openai)) 历史上，Achieve 围绕旨在解决尼古丁成瘾的临床研究而建立，其当前战略仍然高度集中而非多元化。该公司将自己描述为一家后期专业制药企业，这对投资者很重要，因为它表明了一种由临床里程碑、监管事件和最终商业化驱动的开发模式，而不是广泛的上市产品组合。实际上，ACHV 本质上是一个单一资产的故事，股东价值严重依赖于 cytisinicline 的临床、监管和上市执行。([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/257/achieve-life-sciences-announces-up-to-354-million-private-placement?utm_source=openai)) 从竞争角度来看，Achieve 瞄准了一个庞大但服务不足的公共卫生市场：戒烟和更广泛的尼古丁依赖治疗。该公司将 cytisinicline 定位为在一个多年来创新有限的治疗领域中潜在的新选择。因此，其核心活动包括药物开发、生产准备、监管准备和商业化规划。2026 年 4 月，Achieve 宣布完成向美国 Adare Pharma Solutions 的生产技术转让，这一运营步骤加强了其在美国可能上市的准备。([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/256/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions?utm_source=openai)) 从地理上看，该公司的运营基地主要在北美，在美国设有总部并在温哥华设有业务，而管理层已将商业化机会描述为全球性的。对于投资者而言，ACHV 代表了一个经典的市值较小生物技术催化剂概况：上涨空间取决于监管进展，而非当前产品收入多元化。近期一个关键里程碑是 FDA PDUFA 针对 cytisinicline 戒烟的行动目标日期为 2026 年 6 月 20 日。管理层还强调了潜在的更大戒除电子烟机会，该公司最近宣布了一项高达 354 million 美元的私募，并于 2026 年 5 月任命 Andrew D. Goldberg 为首席执行官，并增加了董事会和商业领导层成员。([ir.achievelifesciences.com](https://ir.achievelifesciences.com/news-events/press-releases/detail/247/achieve-life-sciences-reports-third-quarter-2025-financial-results-provides-updates-on-cytisinicline-program?utm_source=openai))
